Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q1 FY2026 other income / expenses was -$840K, compared with -$1.03M a year earlier. Trailing-twelve-month other income / expenses was -$3.53M.
Context
- Other income / expenses amounted to 5.8% of revenue in FY2025, up 2.7 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$840K or moves back toward the trailing-twelve-month quarterly average of -$881.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (4.63M) USD
- Year-over-year change
- -282.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.63M) | -282.3% |
| FY2024 | 2024-12-31 | (1.21M) | -340.8% |
| FY2023 | 2023-12-31 | 503K | +166.1% |
| FY2022 | 2022-12-31 | (761K) | -65.4% |
| FY2021 | 2021-12-31 | (460K) | — |
Other Income / Expenses vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 other income / expenses of -$3.53M is the 8th highest of the 10 companies compared; the peer median is -$1.86M.
- Its year-over-year change of -58.3% is the 8th highest of 10, against a peer median of -29.9%.
- Other income / expenses amounts to 4.1% of revenue for ETON, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $182.15M | +5325.1% | +79.3% | 148.9% | |
| LTM Sep 2026 | $21.61M | +11.8% | -76.4% | 2.3% | |
| LTM Mar 2026 | $6.42M | -36.5% | +80.0% | — | |
| LTM Mar 2026 | $1.66M | -21.3% | +67.5% | — | |
| LTM Mar 2026 | -$1.86M | -1250.0% | — | 2.7% | |
| LTM Mar 2026 | -$2.64M | -29.9% | — | 5.2% | |
| LTM Mar 2026 | -$3.5M | +18.6% | — | 0.9% | |
| LTM Mar 2026 | -$3.53M | -58.3% | — | 4.1% | |
| LTM Sep 2026 | -$26.23M | -1115.7% | — | 4.0% | |
| LTM Mar 2026 | -$43.77M | -30.4% | — | 6.5% | |
| Peer median (excluding ETON) | -$1.86M | -29.9% | +73.4% | 4.0% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.